My Account

Change your country

Login - Register


Your Shopping Cart is empty.

Order on-line




Delphi Genetics is currently hiring
 Delphi is currently hiring two new employees: -one Scientist / QA for its

read more

Delphi Genetics will be present at Lipinov meeting on November 23 and 24
 Delphi genetics will attend the Lipinov meeting in Paris on November 23 an

read more

Delphi Genetics will be present in Munich at BIO europe
 Delphi Genetics will be present at Bio Europe 2015 in Munich on November 2

read more

Delphi Genetics will be present at BIO 2015 international convention in Philadelphia
 Delphi Genetics will be part of the Belgian delegation to BIO 2015 interna

read more


New Products

You are here : News

You may select a news to view :
< previous next >

Delphi Genetics grants GlaxoSmithKline a Licence for the use of the StabyExpress system

22 Sep 2010

Delphi Genetics grants GlaxoSmithKline a Licence for the use of the StabyExpress system

A new technology allowing high-yield vaccine protein biosynthesis
without the use of antibiotics

Charleroi, Belgium, 22nd of September 2010
The StabyExpress system improves the efficiency of protein production and offers the potential of increased protein yield in the manufacture of recombinant vaccines, without the use of antibiotics, whilst reducing the environmental impact. Any proteins manufactured using the StabyExpress system are therefore free of trace levels of antibiotics.
 - Delphi Genetics SA (“Delphi”) has announced today the signature of a licensing agreement with GlaxoSmithKline (GSK) for the use of the patented StabyExpress technology for the production of protein vaccines for human use.
This agreement enables GSK to use, non-exclusively, the technology for the production of vaccine proteins for human use. In exchange for this right of use, Delphi Genetics will receive payments at each development stage of a new protein and will also receive royalties during the marketing phase. The financial details of the agreement have not been revealed.
Philippe Gabant PhD, Delphi Genetics Founder and Business Development Director, explained: “This is the second licensing agreement that we have announced with one of the major vaccine manufacturers. This demonstrates that our technology gives a competitive edge to our biopharmaceutical production partners and shows the importance of our technology in the bioindustrial world. The non-exclusive nature of this licence enables us to consider similar collaborations with other strategic partners, including partners in other fields than vaccine production”.

In June 2009, Delphi Genetics announced a licensing agreement with Sanofi-Pasteur, the human vaccines division of Sanofi-Aventis. That agreement allows Sanofi-Pasteur to implement the StabyExpress technology in its recombinant vaccine production and therefore to be able to produce efficiently without the use of antibiotics. 

About StabyExpress
StabyExpress technology can be applied to any industrial protein production process that involves bacterial fermentation. Biopharmaceutical production represents a booming market and its share of the overall medication market today is estimated to15%. Moreover, the technology is consistent with the recommendations of the FDA and the EMEA with regard to the elimination of Antibiotic Resistance Genes in protein production processes for both human and veterinary uses. Currently, Antibiotic Resistance Genes are used as selection markers for the design of the majority of the genetic systems enabling protein production. 

 About Delphi Genetics SA
Founded at the end of 2001, Delphi Genetics develops more effective products and technologies for genetic engineering and for protein expression in bacteria by using its unique expertise in the field of plasmid stabilisation systems. Delphi Genetics' patented StabyExpress technology increases the recombinant protein production output without the use of antibiotics which is the traditional approach. For further information, please visit our website or contact us.

Contact for Delphi Genetics SA
Tel: +32 71 25 10 00 

< previous next >